282526-98-1 | 2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one

Packsize	Purity	Availability	Price	Discounted Price
50mg	95%	in stock	$16.00	$11.00
1g	95%	in stock	$18.00	$12.00
5g	95%	in stock	$34.00	$24.00
10g	95%	in stock	$44.00	$31.00
25g	95%	in stock	$92.00	$64.00
50g	95%	in stock	$182.00	$127.00
100g	95%	in stock	$297.00	$208.00

Description

• Catalog Number: AI46486
• Chemical Name: 2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
• CAS Number: 282526-98-1
• Molecular Formula: C25H39NO3
• Molecular Weight: 401.5821
• MDL Number: MFCD09839697
• SMILES: CCCCCCCCCCCCCCCCOc1nc2ccc(cc2c(=O)o1)C

Computed Properties

• Complexity: 477
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 16
• XLogP3: 9.8

Literature

• Recent advancements in drug treatment of obesity.

  Clinical medicine (London, England) 20121001

• Non-systemic drugs: a critical review.

  Current pharmaceutical design 20120401

• [The pharmacological treatment of obesity: past, present and future].

  Orvosi hetilap 20120311

• Anti-Obesity Drugs: A Review about Their Effects and Safety.

  Diabetes & metabolism journal 20120201

• Current and future drug targets in weight management.

  Pharmaceutical research 20110801

• Pharmacological treatment of obesity in children and adolescents: present and future.

  Journal of obesity 20110101

• Management of diabetes across the course of disease: minimizing obesity-associated complications.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• [Recent progress and novel perspectives on obesity pharmacotherapy].

  Arquivos brasileiros de endocrinologia e metabologia 20100801

• Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

  Obesity (Silver Spring, Md.) 20100101

• [Drug treatment of obesity--current situation and perspectives].

  Casopis lekaru ceskych 20100101

• Tackling obesity: new therapeutic agents for assisted weight loss.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.

  British journal of clinical pharmacology 20090301

• Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20080801

• Cetilistat, a new lipase inhibitor for the treatment of obesity.

  Current opinion in investigational drugs (London, England : 2000) 20080401

• Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.

  International journal of obesity (2005) 20070301

• Obesity drugs in clinical development.

  Current opinion in investigational drugs (London, England : 2000) 20060401